来源：央视网 近日天气多变，呼吸道疾病高发。很多人认为吃药时最好也用热水，对肠胃和身体更友好。然而从科学 服药角度来看并非如此。"热水送药并不总是对的。"广州市红十字会医院药学部主任、广州市临床用药 质控中心主任张述耀在接受媒体采访时表示，"用热水（尤其是超过40℃的水）送服某些药物，会破坏 药效，甚至增加风险。临床中，我们就曾遇到过因用热水送服肠溶胶囊导致胃部不适、药物无效的案 例。"原来，服药用水也有讲究，用什么样的水送服、水量多少、水温高低等，都可能影响药效。吃胶 囊药不要用热水送服专家介绍，胶囊是临床常见的药物剂型，约占医生开具处方的20%，但它有个弱点 ——怕热水。根据胶囊"囊材"的不同，可分为明胶胶囊和植物胶囊。其中，明胶是应用最多的成囊材 料，这是一种蛋白质制品，成分中85%~90%为蛋白质，不溶于冷水，但容易在温水和热水中溶解。有 试验发现，胶囊在50℃的水里浸泡10秒钟，就会变软、变黏稠。哪怕胶囊外壳只是化了一部分，也会变 得像粘了一块泡泡糖一样，拉丝、发黏。胶囊长时间和食管接触、在错误位置溶解、药物提前释放，可 能会带来以下健康风险。1、损伤食管若胶囊粘在食管，可能在食管局部形成高渗环境， ...

转自：央视网 近日天气多变，呼吸道疾病多发。很多人认为吃药时最好也用热水，对肠胃和身体更友好。然而从科学 服药角度来看并非如此。 "热水送药并不总是对的。"广州市红十字会医院药学部主任、广州市临床用药质控中心主任张述耀在接 受媒体采访时表示，"用热水（尤其是超过40℃的水）送服某些药物，会破坏药效，甚至增加风险。临 床中，我们就曾遇到过因用热水送服肠溶胶囊导致胃部不适、药物无效的案例。" 生病服药的时候，应该喝凉水还是热水？能否用茶水或饮料代替？其实，服药用水也有讲究，用什么样 的水送服、水量多少、水温高低等，都可能影响药效。 吃胶囊药不要用热水送服 专家介绍，胶囊是临床常见的药物剂型，但它有个弱点——怕热水。 根据胶囊"囊材"的不同，可分为明胶胶囊和植物胶囊。其中，明胶是应用最多的成囊材料，这是一种蛋 白质制品，成分中85%~90%为蛋白质，不溶于冷水，但容易在温水和热水中溶解。 有试验发现，胶囊在50℃的水里浸泡10秒钟，就会变软、变黏稠。哪怕胶囊外壳只是化了一部分，也会 变得像粘了一块泡泡糖一样，拉丝、发黏。 胶囊长时间和食管接触、在错误位置溶解、药物提前释放，可能会带来以下健康风险。 损伤食管 若胶囊 ...

Core Viewpoint - Yuheng Pharmaceutical's stock has shown a significant increase this year, with a 40.96% rise, despite recent fluctuations in trading volume and net capital outflow [1][2]. Financial Performance - For the period from January to September 2025, Yuheng Pharmaceutical reported a revenue of 1.665 billion yuan, a year-on-year decrease of 10.36%. However, the net profit attributable to shareholders increased by 32.85% to 244 million yuan [2]. - The company has distributed a total of 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 14, Yuheng Pharmaceutical's stock price was 3.51 yuan per share, with a market capitalization of 7.883 billion yuan. The stock experienced a 2.03% increase during the trading session [1]. - The trading volume indicated a net outflow of 5.7995 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of November 10, the number of shareholders for Yuheng Pharmaceutical was 104,800, a decrease of 0.66% from the previous period. The average number of circulating shares per person increased by 0.85% to 20,038 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 66.3697 million shares, an increase of 35.1366 million shares from the previous period [3]. Business Overview - Yuheng Pharmaceutical, established on March 27, 2000, and listed on June 23, 2010, is primarily engaged in the production and sales of pharmaceuticals. Its main revenue sources include vitamin drugs (43.88%), cardiovascular drugs (28.00%), and orthopedic drugs (10.72%) [1].

Group 1 - The core viewpoint of the news is that Yuheng Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with a notable decrease in revenue but an increase in net profit [1][2]. - As of November 11, Yuheng Pharmaceutical's stock price remained unchanged, with a trading volume of 148 million yuan and a net financing outflow of 847,300 yuan [1]. - The company's financing balance is 371 million yuan, accounting for 4.94% of its market capitalization, which is above the 60th percentile of the past year [1]. Group 2 - For the period from January to September 2025, Yuheng Pharmaceutical reported a revenue of 1.665 billion yuan, a year-on-year decrease of 10.36%, while the net profit attributable to shareholders increased by 32.85% to 244 million yuan [2]. - The number of shareholders increased by 2.88% to 105,500, while the average number of circulating shares per person decreased by 2.80% to 19,869 shares [2]. - The company has distributed a total of 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

Core Insights - On October 23, Yuheng Pharmaceutical experienced a decline of 1.53% with a trading volume of 137 million yuan, indicating a negative market sentiment towards the company [1] - The company reported a financing net buy of -3.40 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 23, the total margin balance for Yuheng Pharmaceutical stood at 380 million yuan, which is 5.37% of its circulating market value, indicating a relatively high leverage position [1] Financing and Margin Data - On October 23, the financing buy amount was 14.50 million yuan, while the financing repayment was 17.90 million yuan, leading to a net financing outflow [1] - The current financing balance of 380 million yuan exceeds the 70th percentile level over the past year, indicating a significant level of borrowing [1] - In terms of securities lending, there were no shares sold on October 23, with a total of 0 shares in the lending balance, which is at the 80th percentile level over the past year [1] Company Financial Performance - As of September 19, the number of shareholders for Yuheng Pharmaceutical was 105,700, a decrease of 1.03% from the previous period, while the average circulating shares per person increased by 1.04% to 19,831 shares [2] - For the first half of 2025, the company reported a revenue of 1.10 billion yuan, a year-on-year decrease of 9.97%, while the net profit attributable to shareholders was 134 million yuan, reflecting a year-on-year increase of 7.56% [2] Dividend and Shareholding Information - Since its A-share listing, Yuheng Pharmaceutical has distributed a total of 692 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 31.23 million shares as a new shareholder [3]

Core Insights - On September 30, Yuheng Pharmaceutical experienced a decline of 0.96% with a trading volume of 106 million yuan, indicating a challenging market environment [1] - The company reported a net financing outflow of 13.63 million yuan on the same day, with a total financing and securities balance of 389 million yuan, which is 5.74% of its market capitalization [1] - As of September 19, the number of shareholders decreased by 1.03% to 105,700, while the average circulating shares per person increased by 1.04% to 19,831 shares [2] Financial Performance - For the first half of 2025, Yuheng Pharmaceutical achieved a revenue of 1.1 billion yuan, reflecting a year-on-year decrease of 9.97%, while the net profit attributable to shareholders increased by 7.56% to 134 million yuan [2] - Cumulatively, the company has distributed 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholding Structure - As of June 30, 2025, Hong Kong Central Clearing Limited emerged as the fourth largest circulating shareholder, holding 31.23 million shares as a new investor [3]

Core Insights - On September 24, Yuheng Pharmaceutical's stock increased by 0.31%, with a trading volume of 130 million yuan [1] - The company reported a financing buy-in of 10.47 million yuan and a financing repayment of 11.27 million yuan, resulting in a net financing outflow of 799,100 yuan [1] - As of September 24, the total margin balance for Yuheng Pharmaceutical was 409 million yuan, representing 5.81% of its market capitalization [1] Financing Overview - On the same day, the financing buy-in was 10.47 million yuan, with a current financing balance of 409 million yuan, which is above the 80th percentile level over the past year [1] - In terms of securities lending, there were no shares repaid or sold on September 24, with a remaining loan balance of 321 yuan, also exceeding the 80th percentile level over the past year [1] Company Performance - As of September 19, the number of shareholders for Yuheng Pharmaceutical was 105,700, a decrease of 1.03% from the previous period [2] - For the first half of 2025, the company reported a revenue of 1.1 billion yuan, a year-on-year decrease of 9.97%, while the net profit attributable to shareholders was 134 million yuan, reflecting a year-on-year increase of 7.56% [2] Dividend History - Since its A-share listing, Yuheng Pharmaceutical has distributed a total of 692 million yuan in dividends, with no dividends paid in the last three years [3] Shareholding Structure - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest shareholder among the top ten circulating shareholders, holding 31.23 million shares as a new investor [3]